BR112021021306A2 - Ecas9 modificada com ampliação da faixa de alvo de dna - Google Patents

Ecas9 modificada com ampliação da faixa de alvo de dna

Info

Publication number
BR112021021306A2
BR112021021306A2 BR112021021306A BR112021021306A BR112021021306A2 BR 112021021306 A2 BR112021021306 A2 BR 112021021306A2 BR 112021021306 A BR112021021306 A BR 112021021306A BR 112021021306 A BR112021021306 A BR 112021021306A BR 112021021306 A2 BR112021021306 A2 BR 112021021306A2
Authority
BR
Brazil
Prior art keywords
ecas9
modified
target range
dna target
range amplification
Prior art date
Application number
BR112021021306A
Other languages
English (en)
Inventor
Le Cong
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BR112021021306A2 publication Critical patent/BR112021021306A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ecas9 modificada com ampliação da faixa de alvo de dna. a divulgação fornece variantes da proteína cas9 (sacas9) de staphylococcus aureus com especificidade alterada para sequências de motif adjacente de protoespaçador (pam). a divulgação também é direcionada a sistemas crispr / cas9 e métodos de alteração de uma sequência de dna genômico usando a variante da proteína sacas9. métodos de geração de variantes da proteína cas9 com especificidade pam alterada também são divulgados.
BR112021021306A 2019-04-25 2020-04-24 Ecas9 modificada com ampliação da faixa de alvo de dna BR112021021306A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838498P 2019-04-25 2019-04-25
PCT/US2020/029855 WO2020219908A1 (en) 2019-04-25 2020-04-24 Engineered cas9 with broadened dna targeting range

Publications (1)

Publication Number Publication Date
BR112021021306A2 true BR112021021306A2 (pt) 2022-02-01

Family

ID=72941444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021306A BR112021021306A2 (pt) 2019-04-25 2020-04-24 Ecas9 modificada com ampliação da faixa de alvo de dna

Country Status (12)

Country Link
US (1) US20220204954A1 (pt)
EP (1) EP3958914A4 (pt)
JP (1) JP2022530055A (pt)
KR (1) KR20220025708A (pt)
CN (1) CN114206394A (pt)
AU (1) AU2020261071A1 (pt)
BR (1) BR112021021306A2 (pt)
CA (1) CA3137903A1 (pt)
IL (1) IL287541A (pt)
MX (1) MX2021012966A (pt)
SG (1) SG11202111814XA (pt)
WO (1) WO2020219908A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117866926A (zh) * 2024-03-07 2024-04-12 珠海舒桐医疗科技有限公司 一种CRISPR-FrCas9蛋白突变体及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141224A1 (en) * 2015-03-03 2016-09-09 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US9512446B1 (en) * 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
JP7231935B2 (ja) * 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
EP3559223A1 (en) * 2016-12-23 2019-10-30 President and Fellows of Harvard College Gene editing of pcsk9
EP3680331A4 (en) * 2017-09-05 2021-06-09 The University Of Tokyo MODIFIED CAS9 PROTEIN AND USING IT

Also Published As

Publication number Publication date
US20220204954A1 (en) 2022-06-30
WO2020219908A1 (en) 2020-10-29
AU2020261071A1 (en) 2021-11-25
CA3137903A1 (en) 2020-10-29
KR20220025708A (ko) 2022-03-03
MX2021012966A (es) 2022-04-06
EP3958914A1 (en) 2022-03-02
CN114206394A (zh) 2022-03-18
IL287541A (en) 2021-12-01
JP2022530055A (ja) 2022-06-27
SG11202111814XA (en) 2021-11-29
EP3958914A4 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
WO2019006471A3 (en) NOVEL CRISPR RNA TARGETING ENZYMES, SYSTEMS AND USES THEREOF
BR112019004629A2 (pt) variantes de endonuclease de homing pd-1, composições e métodos de uso
AU2018320870A1 (en) RNA targeting methods and compositions
EP4275747A3 (en) Therapeutic applications of cpf1-based genome editing
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
WO2019009682A3 (ko) 표적 특이적 crispr 변이체
WO2017053431A3 (en) Allele selective gene editing and uses thereof
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
BR112017024534A2 (pt) sistemas de rna-guia/endonuclease cas9 inovadores
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
BR112016028255A2 (pt) agentes imunorreguladores
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
WO2016183402A3 (en) Methods of making and using guide rna for use with cas9 systems
BR112017014986A2 (pt) erradicação guiada por rna de herpes simples tipo i e outros herpesvírus relacionados
PH12015502028A1 (en) Ido inhibitors
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2019209885A3 (en) Enzyme engineering to alter the functional repertoire of cannabinoid synthases
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
BR112022003970A2 (pt) Métodos e composições para integração genômica
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).